NCT07260253Recruiting
Remotely-supervised Neuromodulation in PPA
Investigating the Benefits of Remotely-Supervised Neuromodulation In Primary Progressive Aphasia
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia (lvPPA), a language disorder most often caused by Alzheimer's disease. The main questions the study aims to answer are: * Is combining remotely supervised transcranial direct current stimulation (tDCS) with virtual speech-language therapy feasible and acceptable for people with lvPPA? * Does this combined treatment lead to improvements in communication compared to speech-language therapy with sham (placebo) stimulation? * Do individual brain characteristics help predict who benefits most from this treatment? Researchers will compare participants who receive active tDCS plus virtual speech-language therapy to participants who receive sham (placebo) tDCS plus virtual speech-language therapy to see if active brain stimulation enhances communication outcomes. Participants will: * Complete speech-language therapy sessions delivered by video visit. * Receive either active or sham tDCS that is remotely supervised and completed at home. * Complete language and cognitive testing before and after treatment. * Undergo brain imaging and other assessments to help understand treatment response.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 6 Oct 2025
- Start date
- 15 Apr 2026
- Primary completion date
- 1 Apr 2030
- Lead sponsor
- Maya Henry
- Diseases
- Frontotemporal dementia, Alzheimer disease
- NCT number
- NCT07260253
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 15 Apr 2026 to the primary completion date, 1 Apr 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Speech and language deficits better accounted for by another neurological disorder
- Has contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head; Pacemaker or cardioverter-defibrillator or any other stimulator; Chronic skin problems; Pregnancy)
- Has a history of stroke, epilepsy, or significant brain injury
Other
- Does not meet diagnostic criteria for logopenic variant PPA
- Scores less than 15 on the Mini-Mental State Examination
- Does not have a study partner who can co-enroll in the study
Who the study is looking for
- Meets diagnostic criteria for primary progressive aphasia (PPA)
- Meets diagnostic criteria for logopenic variant PPA
- Attains score of 15 or higher on the Mini-Mental State Examination
- Has adequate hearing and vision (with hearing or vision aids, if needed)
- Is able to travel to research site and undergo MRI brain scan
- Has access to high speed internet and basic experience using a computer and the internet
- Is a fluent speaker of English
- Has a study partner who can co-enroll in the study, attend pre-treatment training at the research site, and be present for teleconference meetings, as needed
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas Coordinator of this site? Confirm its status | Austin | United States | Recruiting |
| UCSF Memory and Aging Cener Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.